FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	205/10
wasiiiigton,	D.C.	20349

STATEMENT	OF CHANGES	S IN BENEFICIAL	L OWNERSHIP

OMB APPROVAL						
OMB Number: 3235-0287						
Estimated average burden						
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Ebbers Ed</u>					2. Issuer Name and Ticker or Trading Symbol Pulse Biosciences, Inc. [PLSE]						(Che	ck all applica	tionship of Reporting all applicable) Director		10% Ow	ner
(Last) 3957 PO	(F INT EDEN	irst) WAY	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/23/2021						X	X Officer (give title below) Other (specify below) EVP & GM, Dermatology				
(Street) HAYWA		itate)	94545 (Zip)	_	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person											
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Trans. Date (Month/I			•	action 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4)						Form: D (D) or Ir		'. Nature of ndirect Beneficial Ownership Instr. 4)		
					Code V Amount (A) or (D)					Price	Transaction(s) (Instr. 3 and 4)					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio	e S Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	un(s)		
Stock Option (right to buy)	\$10.66	02/23/2021		A		37,500 ⁽¹⁾		(1)	05/18/2030	Common Stock	37,500	\$0.00	37,500	0	D	
Stock Option (right to buy)	\$24.03	03/22/2021		A		15,875		03/01/2022 ⁽²⁾	03/22/2031	Common Stock	15,875	\$0.00	15,875	5	D	

Explanation of Responses:

- 1. Represents the acquisition of vested options upon the determination of the Compensation Committee of the Board of Directors of the Issuer that certain performance conditions were met in 2020 with respect to performance-based stock options granted to the Reporting Person on May 18, 2020.
- 2. The shares subject to the option will vest in equal annual installments over the following four years on the anniversary of March 1, 2021, subject to the Reporting Person's continued service through each vesting

Remarks:

/s/ Sandra Gardiner, as Attorney-in-Fact

03/24/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.